Independent Data Monitoring Committee (IDMC) Recommends CONTESSA Continue with No Modifications following Planned Interim Efficacy Futility Analysis

SAN DIEGO–(BUSINESS WIRE)–Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that the IDMC for CONTESSA, Odonate?s Phase 3 study investigating tesetaxel as a potential treatment for patients with HER2 negative, hormone receptor positive metastatic breast cancer, recommended that the study continue with no modifications following a planned interi